Top

PharmacoEconomics

Published in:

01-06-2009 | Leading Article

Cost Effectiveness of Influenza Vaccination in Older Adults

A Critical Review of Economic Evaluations for the 50- to 64-Year Age Group

Authors: Anthony T. Newall, Heath Kelly, Stuart Harsley, Prof. Paul A. Scuffham

Published in: PharmacoEconomics | Issue 6/2009

Abstract

Several recent studies have assessed the benefits of extending influenza vaccination programmes, which are currently targeted primarily at those aged over 65 years, to those aged 50–64 years. We identified and reviewed all costeffectiveness studies of influenza vaccination in those aged 50–64 years published before July 2008. While the studies suggest that vaccination in this age-group is likely to be cost effective, these results were dependent on several key assumptions. The estimates of serious outcomes due to influenza and the estimates of vaccine effectiveness (VE) against these outcomes were found to have the most influence on cost effectiveness. However, due to factors including mismatches between the measure of VE and the outcome under consideration, as well as various other data limitations, there is significant uncertainty around these key assumptions that was not well explored. There was a failure in some studies to report fundamental inputs such as discount rates. Overall, there was a general lack of transparency in the studies and, consequently, the conclusions around the cost effectiveness of influenza vaccine in those aged 50–64 years must be interpreted with caution.

Li CK, Choi BC, Wong TW. Influenza-related deaths and hospitalizations in Hong Kong: a subtropical area. Public Health 2006; 120 (6): 517–24PubMedCrossRef

Newall AT, Wood JG, Macintyre CR. Influenza-related hospitalisation and death in Australians aged 50 years and older. Vaccine 2008; 26 (17): 2135–41PubMedCrossRef

Thompson W, Shay D, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289: 179–86PubMedCrossRef

Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA 2004; 292 (11): 1333–40PubMedCrossRef

Lee PY, Matchar DB, Clements DA, et al. Economic analysis of influenza vaccination and antiviral treatment for healthy working adults. Ann Intern Med 2002; 137 (4): 225–31PubMed

Nichol KL. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza. Arch Intern Med 2001; 161 (5): 749–59PubMedCrossRef

Nichol KL, Mallon KP, Mendelman PM. Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine. Vaccine 2003; 21 (17–18): 2207–17PubMedCrossRef

Rothberg MB, Rose DN. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis. Am J Med 2005; 118 (1): 68–77PubMedCrossRef

Wood SC, Nguyen VH, Schmidt C. Economic evaluations of influenza vaccination in healthy working-age adults: employer and society perspective. Pharmacoeconomics 2000; 18 (2): 173–83PubMedCrossRef

10.

Drummond M, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press, 2005

11.

Koopmanschap MA, Rutten FF, van Ineveld BM, et al. The friction cost method for measuring indirect costs of disease. J Health Econ 1995; 14 (2): 171–89PubMedCrossRef

12.

Australian Institute of Health and Welfare. 2004 adult vaccination survey: summary results. Canberra: AIHW & DoHA, 2005. Report no.: PHE 56

13.

Blank PR, Schwenkglenks M, Szucs TD. Influenza vaccination coverage rates in five European countries during season 2006/07 and trends over six consecutive seasons. BMC Public Health 2008; 8 (1): 272PubMedCrossRef

14.

Bridges CB, Winquist AG, Fukuda K, et al. Prevention and control of influenza: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 2000; 49 (RR-3): 1–38.PubMed

15.

Pitman RJ, Melegaro A, Gelb D, et al. Assessing the burden of influenza and other respiratory infections in England and Wales. J Infect 2007; 54 (6): 530–38PubMedCrossRef

16.

Aballea S, Chancellor J, Martin M, et al. The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model. Value Health 2007; 10 (2): 98–116PubMedCrossRef

17.

Aballea S, De Juanes JR, Barbieri M, et al. The cost effectiveness of influenza vaccination for adults aged 50 to 64 years: a model-based analysis for Spain. Vaccine 2007; 25 (39–40): 6900–10PubMedCrossRef

18.

Maciosek MV, Solberg LI, Coffield AB, et al. Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older. Am J Prev Med 2006; 31 (1): 72–9PubMedCrossRef

19.

Newall AT, Scuffham PA, Kelly H, et al. The cost-effectiveness of a universal influenza vaccination program for adults aged 50–64 years in Australia. Vaccine 2008; 26 (17): 2142–53PubMedCrossRef

20.

Prosser LA, O’Brien MA, Molinari NA, et al. Non-traditional settings for influenza vaccination of adults: costs and cost effectiveness. Pharmacoeconomics 2008; 26 (2): 163–78PubMedCrossRef

21.

Turner DA, Wailoo AJ, Cooper NJ, et al. The cost-effectiveness of influenza vaccination of healthy adults 50–64 years of age. Vaccine 2006; 24 (7): 1035–43PubMedCrossRef

22.

Lopez L, Huang QS. Influenza in New Zealand 2008. Porirua: Institute of Environmental Science and Research (ESR); 2009 [online]. Available from URL: http://www.surv.esr.cri.nz/virology/influenza_annual_report.php [Accessed 2009 Jun 15]

23.

Newall AT, Beutels P, Wood JG, et al. Cost-effectiveness analyses of human papillomavirus vaccination. Lancet Infect Dis 2007; 7 (4): 289–96PubMedCrossRef

24.

Beutels P, Scuffham PA, MacIntyre CM. Funding of drugs: do vaccines warrant a different approach. Lancet Infect Dis 2008; 8: 727–33PubMedCrossRef

25.

Meltzer MI, Cox NJ, Fukuda K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis 1999; 5 (5): 659–71PubMedCrossRef

26.

Demicheli V, Rivetti D, Deeks JJ, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2004; (3): CD00126

27.

Demicheli V, Rivetti D, Deeks JJ, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2001; (4): CD001269

28.

Gross PA, Hermogenes AW, Sacks HS, et al. The efficacy of influenza vaccine in elderly persons: a meta-analysis and review of the literature. Ann Intern Med 1995; 123 (7): 518–27PubMed

29.

Nichol KL. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine 2003; 21 (16): 1769–75PubMedCrossRef

30.

Jefferson TO, Rivetti D, Di Pietrantonj C, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2007; (2): CD001269

31.

Barker WH, Mullooly JP. Impact of epidemic type A influenza in a defined adult population. Am J Epidemiol 1980; 112 (6): 798–11PubMed

32.

Simonsen L, Taylor RJ, Viboud C, et al. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis 2007; 7 (10): 658–66PubMedCrossRef

33.

Kelly H, Newall AT. Mortality benefits of influenza vaccination in elderly people. Lancet Infect Dis 2008; 8 (8): 462–3PubMedCrossRef

34.

Maciosek MV, Coffield AB, Edwards NM, et al. Methods for prioritizing clinical preventive services: technical report prepared for the National Commission on Prevention Priorities. Minneapolis (MN): HealthPartners Research Foundation, 2006.

35.

Prior G. Self-reported health: health survey for England ‘96. London: The Stationery Office, 1998

36.

Hawthorne G, Osborne R. Population norms and meaningful differences for the Assessment of Quality of Life (AQoL) measure. Aust N Z J Public Health 2005; 29 (2): 136–42PubMedCrossRef

37.

Molinari NA, Ortega-Sanchez IR, Messonnier ML, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007; 25 (27): 5086–96PubMedCrossRef

38.

Grosse SD. Prevention effectiveness: a guide to decision analysis and economic evaluation [appendix I: productivity loss tables]. 2nd ed. New York: Oxford University Press, 2003

39.

Scuffham PA, West PA. Economic evaluation of strategies for the control and management of influenza in Europe. Vaccine 2002; 20 (19–20): 2562–78PubMedCrossRef

40.

Scuffham PA, Whitty JA, Mitchell AM, et al. The use of QALY weights for QALY calculations. Pharmacoeconomics 2008; 26 (4): 297–310PubMedCrossRef

Title: Cost Effectiveness of Influenza Vaccination in Older Adults
A Critical Review of Economic Evaluations for the 50- to 64-Year Age Group
Authors: Anthony T. Newall
Heath Kelly
Stuart Harsley
Prof. Paul A. Scuffham
Publication date: 01-06-2009
Publisher: Springer International Publishing
Published in: PharmacoEconomics / Issue 6/2009
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI: https://doi.org/10.2165/00019053-200927060-00001

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Cost Effectiveness of Influenza Vaccination in Older Adults

A Critical Review of Economic Evaluations for the 50- to 64-Year Age Group

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2009

Holistic Preferences for 1-Year Health Profiles Describing Fluctuations in Health

Economic Outcomes Associated with Microvascular Complications of Type 2 Diabetes Mellitus

Determinants of Direct Cost Differences among US Employees with Major Depressive Disorders Using Antidepressants

Pharmacoeconomic Considerations in Treating Actinic Keratosis

How to Deal with Cost Differences at Baseline

Converting the SF-12 into the EQ-5D